One year ago this week, Novartis biomedical research president Fiona Marshall called artificial intelligence a technology with “the potential to transform how we discover new drugs.” ...

Danielle Rasooly, PhD, of the Division of Aging at Brigham and Women’s Hospital, is the co-corresponding author of a paper published in Nature Cardiovascular Research, “Large-scale multi-omics ...

Ph.D., the global oncology chief at Novartis’ Institutes for BioMedical Research, said during a meet the management event in November. “We think long and hard around both what format we’re ...

Jay Bradner, president of the Novartis Institutes for Biomedical Research (NIBR), is retiring from the position after seven years in the role, and will be replaced by Merck & Co R&D executive ...

Coherus BioSciences, Inc.’s CHRS share price has dipped by 12.59%, which has investors questioning if this is right time to ...

The Micro Immune Response On chip (MIRO) allows tumours and their environment to be replicated in order to understand their response to immunotherapy-based treatments. The device, which has already ...

Novartis experienced a strong bull run in 2024 ... or simply access the investment bank-grade financial models and research. I hope to see you there. Analyst’s Disclosure: I/we have no stock ...

In the same year, it also created the Novartis Institutes for BioMedical Research (NIBR), which headquarters in the US. In 2003, Novartis acquired the worldwide adult medical nutrition business of ...

How would you summarize your study for a lay audience?Heart failure remains a substantial burden for patients due to its high ...

These consortia vary in their scope, funding, and structure from government-funded models such as the National Cancer Institute Experimental ... Sankyo Europe GmbH, Novartis, Pfizer, Ellipses Pharma, ...